These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25683849)

  • 1. PET-adapted salvage therapy in Hodgkin's lymphoma.
    Tirelli U; Spina M
    Lancet Oncol; 2015 Mar; 16(3):239-40. PubMed ID: 25683849
    [No Abstract]   [Full Text] [Related]  

  • 2. PET-adapted salvage therapy for Hodgkin's lymphoma.
    Laffon E; Marthan R
    Lancet Oncol; 2015 May; 16(5):e197-8. PubMed ID: 25943059
    [No Abstract]   [Full Text] [Related]  

  • 3. PET-adapted salvage therapy for Hodgkin's lymphoma--authors' reply.
    Schöder H; Moskowitz CH; Moskowitz AJ
    Lancet Oncol; 2015 May; 16(5):e198. PubMed ID: 25943060
    [No Abstract]   [Full Text] [Related]  

  • 4. PET-Directed Therapy for Hodgkin's Lymphoma.
    Bishop G
    N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200988
    [No Abstract]   [Full Text] [Related]  

  • 5. PET-Directed Therapy for Hodgkin's Lymphoma.
    Radford J; Illidge T; Barrington S
    N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200987
    [No Abstract]   [Full Text] [Related]  

  • 6. PET after chemotherapy identifies Hodgkin's lymphoma patients who can avoid radiotherapy.
    Mayor S
    BMJ; 2015 Apr; 350():h2190. PubMed ID: 25908591
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.
    Ugocsai P; Wolff D; Menhart K; Hellwig D; Holler E; Herr W; Reichle A
    Br J Haematol; 2016 Jan; 172(2):290-3. PubMed ID: 25944562
    [No Abstract]   [Full Text] [Related]  

  • 8. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalised approach to treating early Hodgkin's lymphoma.
    Illidge T
    BMJ; 2015 Jun; 350():h2927. PubMed ID: 26038281
    [No Abstract]   [Full Text] [Related]  

  • 10. Fine-Tuning the Treatment of Hodgkin's Lymphoma.
    Bartlett NL
    N Engl J Med; 2016 Jun; 374(25):2490-2. PubMed ID: 27332908
    [No Abstract]   [Full Text] [Related]  

  • 11. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    George B; Benson W; Hertzberg MS
    Bone Marrow Transplant; 2012 Jul; 47(7):1001-2. PubMed ID: 22002487
    [No Abstract]   [Full Text] [Related]  

  • 13. Controversies in the treatment of early-stage Hodgkin's lymphoma.
    Longo DL; Armitage JO
    N Engl J Med; 2015 Apr; 372(17):1667-9. PubMed ID: 25901431
    [No Abstract]   [Full Text] [Related]  

  • 14. A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma.
    Todeschini G; Bonifacio M; Tecchio C; Dalceggio D; Benedetti F; Gabbas A; Pizzolo G
    Hematol Oncol; 2011 Sep; 29(3):151-3. PubMed ID: 20872912
    [No Abstract]   [Full Text] [Related]  

  • 15. Hodgkin's lymphoma--the great teacher.
    Connors JM
    N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
    [No Abstract]   [Full Text] [Related]  

  • 16. Escalated BEACOPP in advanced Hodgkin's lymphoma.
    Casasnovas O; Coiffier B
    Lancet; 2012 May; 379(9828):1767-8. PubMed ID: 22480757
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Laport GF; Williams SF
    Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
    Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
    Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
    Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.